Andrew Fromkin

Andrew J.
Fromkin is currently Director at Immunovant Sciences Ltd. since 2019, Director at Immunovant, Inc. since 2019, and Partner at Roivant Sciences, Inc. since 2021.
Formerly, Mr. Fromkin was Chief Executive Officer at Clinical Data, Inc. in 2011; President, Chief Executive Officer & Director at Radius Health, Inc. in 2013; President & Chief Executive Officer at DoctorQuality, Inc. from 2000 to 2004; Chairman & Chief Executive Officer at Tarveda Therapeutics, Inc. from 2020 to 2021; Chief Executive Officer at Proteovant Sciences, Inc. from 2021 to 2023; President, Chief Executive Officer & Director at Endo Surgical Devices, Inc. from 2001 to 2002; Director at Regado Biosciences, Inc. from 2014 to 2016; Director at Avalon Pharmaceuticals, Inc. in 2009; Independent Director at Tobira Therapeutics, Inc. from 2015 to 2016; Director at Immunovant, Inc.; Director-Marketing & Payer Alliance at Health Information Technology from 1988 to 1993; and Vice President-Business Development at Merck-Medco Managed Care LLC from 1993 to 2000.
Mr. Fromkin completed undergraduate education at Brandeis University.